CoChat

SGLT-2 Inhibitors and Cardiovascular Risk

Open access
Cavender, Matthew A., Norhammar, Anna, Birkeland, Kåre I., Jørgensen, Marit Eika, Wilding, John P., Khunti, Kamlesh, Fu, Alex Z., Bodegård, Johan, Blak, Betina T., Wittbrodt, Eric, Thuresson, Marcus, Fenici, Peter, Hammar, Niklas, Kosiborod, Mikhail, Kosiborod, Mikhail, Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Norhammar, Anna, Birkeland, Kåre I, Jørgensen, Marit Eika, Holl, Reinhard W., Hammar, Niklas, Fenici, Peter, Chen, Hungta, Bodegård, Johan, Blak, Betina T., Wittbrodt, Eric T., Scheerer, Markus F, Surmont, Filip, Nahrebne, Kyle, Gulseth, Hanne Løvdal, Carstensen, Bendix, Thuresson, Marcus, Bollow, Esther, García Rodríguez, Luis Alberto, Cea Soriano, Lucia, Cantero, Oscar Fernándex, Thiel, Ellen, Murphy, Brian · 2018 · Journal of the American College of Cardiology
Cited by 136

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is unknown. OBJECTIVES: This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in patients with and without CVD. METHODS: The CVD-REAL (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors) study was a multinational, observational study in which adults with type 2 diabetes were identified. Patients prescribed an SGLT-2i or other glucose-lowering drugs (GLDs) were matched based on a propensity score for initiation of an SGLT-2i. Hazard ratios (HRs) for the risk of death, HF, and HF or death in patients with and without established CVD were estimated for each country and pooled. RESULTS: After propensity score matching, 153,078 patients were included in each group. At baseline, 13% had established CVD. Compared with therapy using other GLDs, initiation of an SGLT-2i was associated with lower risk of death in patients with and without CVD (HR: 0.56; 95% confidence interval [CI]: 0.44 to 0.70; and HR: 0.56; 95% CI: 0.50 to 0.63, respectively). There were also associations between SGLT-2i and lower risk of HF (HR: 0.72; 95% CI: 0.63 to 0.82; and HR: 0.61; 95% CI: 0.48 to 0.78, respectively) and the composite of HF or death (HR: 0.63; 95% CI: 0.57 to 0.70; and HR: 0.56; 95% CI: 0.50 to 0.62, respectively) observed in patients with and without established CVD. CONCLUSIONS: In this large, multinational, observational study, initiation of SGLT-2i was associated with lower risk of death and HF regardless of pre-existing CVD. Ongoing clinical trials will provide further evidence regarding the benefit of SGLT-2i in patients without established CVD. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2018.01.085

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 136

Metadata

Authors
Cavender, M. A., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Wilding, J. P., Khunti, K., Fu, A. Z., Bodegård, J., Blak, B. T., Wittbrodt, E., Thuresson, M., Fenici, P., Hammar, N., Kosiborod, M., Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Holl, R. W., Hammar, N., Fenici, P., Chen, H., Bodegård, J., Blak, B. T., Wittbrodt, E. T., Scheerer, M. F., Surmont, F., Nahrebne, K., Gulseth, H. L., Carstensen, B., Thuresson, M., Bollow, E., García Rodríguez, L. A., Cea Soriano, L., Cantero, O. F., Thiel, E., & Murphy, B.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2018-06
Volume
71
Issue
22
Pages
2497-2506
ISSN
0735-1097 (ISSN-L)
OpenAlex
W2805417982
Cited by
136
References
11
FWCI
13.82
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SGLT-2 Inhibitors and Cardiovascular Risk. https://app.cochat.ai/papers/10.1016/j.jacc.2018.01.085
The paper
Cavender, M. A., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Wilding, J. P., Khunti, K., Fu, A. Z., Bodegård, J., Blak, B. T., Wittbrodt, E., Thuresson, M., Fenici, P., Hammar, N., Kosiborod, M., Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., . . . Murphy, B. (2018). SGLT-2 Inhibitors and Cardiovascular Risk. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2018.01.085

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.